Compare Futu Holdings Ltd (FUTU) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Futu Holdings Ltd vs ResMed Inc. — how do they compare? Futu Holdings Ltd trades at $111.77 (market cap $15.25B), while ResMed Inc. trades at $228.37 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 2.1× Futu Holdings Ltd's market cap, and Futu Holdings Ltd pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Futu Holdings Ltd for 34 Days and ResMed Inc. for 51 Days on average.
| FUTU | RMD | |
|---|---|---|
Market Cap | $15.25B | $31.89B |
Volume | 812,567 | 618,314 |
Sector | Financials | Health |
52-Week High | $199.04 | $277.88 |
52-Week Low | $89.76 | $182.82 |
Typical Hold Time | 34 Days | 51 Days |
Enterprise Value | $15.59B | $31.24B |
Dividend Yield | 2.39% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Futu Holdings trades at $109.68, down 3.12% today amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 10.86, net income margin of 42.92%, and robust revenue growth from $13.6B in 2024 to $22.85B in 2025. Recent news includes Moomoo's partnership with X's Cashtag program and a class action lawsuit deadline on August 25, 2026.
The outlook is mixed: strong profitability and analyst upside targets near 33% contrast with legal risks and technical weakness. Key risks include lawsuit outcomes and market volatility, while growth drivers are overseas expansion and trading platform adoption. Investors face a balance of high returns potential against significant headline risks.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical signal and strong fundamentals. Revenue grew to $5.15B in 2025, with net income at $1.40B and a 26.94% net margin. Recent earnings beats and a 12-14% EPS growth outlook support momentum. The stock is near its pivot point of $227, with support at $225 and resistance at $228.
Outlook is positive with analyst consensus at Buy and a $242.70 price target. Risks include competitive pressures and ongoing legal investigations. Institutional buying and solid cash flow growth underpin the bullish case, though macroeconomic and regulatory factors warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
